Ligand Pharmaceuticals (LGND) Insider Trading
Officer, director, and 10%+ owner transactions reported to the SEC on Form 4, with buy/sell totals and cluster activity for Ligand Pharmaceuticals.
Bought (12 mo)
$0
Sold (12 mo)
$34,725,549
Insiders Buying (12 mo)
0
Insiders Selling (12 mo)
9
Form 4 Filings (All Time)
245
Most Recent Purchase
May 14, 2025
Todd C Davis
CEO
$1,000,456
Most Recent Sale
October 6, 2026
Andrew Reardon
GC
$1,520,346
Buys (90d)
0
Sells (90d)
6
Recent Insider Transactions
| Filed | Insider | Role | Type | Value | % Change |
|---|---|---|---|---|---|
| 2026-10-06 | Reardon Andrew | Officer | Sell | $1,520,346 | -12.8% |
| 2026-09-24 | Zimmermann Martine | Director | Other | — | -3.0% |
| 2026-09-14 | Zimmermann Martine | Director | Sell | $342,000 | -23.5% |
| 2026-09-08 | Reardon Andrew | Officer | Sell | $1,430,434 | -12.0% |
| 2026-08-14 | Haas Jason | Director | Sell | $2,090,062 | -20.1% |
| 2026-08-14 | Espinoza Octavio | CFO | Sell | $9,241,229 | — |
| 2026-08-04 | Reardon Andrew | Officer | Sell | $1,444,951 | — |
Sign up free to view more insider trades.